GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion

U.K.-based GlaxoSmithKline Plc and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday.